ExodusPoint Capital Management’s Standard BioTools LAB Stock Holding History

ExodusPoint Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1K	Buy	+26,867	New	+$25.4K	﹤0.01%	1493
2024 Q4	–	Sell	-100,309	Closed	-$194K	–	1792
2024 Q3	$194K	Buy	+100,309	New	+$196K	﹤0.01%	1457
2024 Q2	–	Sell	-304,495	Closed	-$825K	–	1764
2024 Q1	$825K	Buy	304,495 +232,470	+323%	+$561K	0.01%	1003
2023 Q4	$159K	Buy	+72,025	New	+$154K	﹤0.01%	1311
2023 Q1	–	Sell	-16,895	Closed	-$20K	–	1957
2022 Q4	$20K	Buy	+16,895	New	+$20.8K	﹤0.01%	1567
2022 Q1	–	Sell	-13,357	Closed	-$52K	–	2448
2021 Q4	$52K	Sell	13,357 -22,895	-63%	-$107K	﹤0.01%	2027
2021 Q3	$239K	Sell	36,252 -20,989	-37%	-$138K	﹤0.01%	1715
2021 Q2	$353K	Buy	+57,241	New	+$306K	﹤0.01%	1642
2021 Q1	–	Sell	-63,039	Closed	-$378K	–	2369
2020 Q4	$378K	Sell	63,039 -120,824	-66%	-$794K	﹤0.01%	1415
2020 Q3	$1.37M	Buy	+183,863	New	+$1.27M	0.03%	551

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

ExodusPoint Capital Management's LAB Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Standard BioTools (LAB) in Q2 2026: 26,867 shares worth $22.1K. The stake represents ﹤0.01% of the portfolio and ranks #1493 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in LAB as recently as Q3 2024.

ExodusPoint Capital Management first reported a position in LAB in Q3 2020 and has held it in 10 quarters since. The position peaked at $1.37M in Q3 2020. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

ExodusPoint Capital Management held 26,867 shares of Standard BioTools worth $22.1K as of Q2 2026.
Standard BioTools was a new ExodusPoint Capital Management position in Q2 2026.
Standard BioTools made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1493 holding.
ExodusPoint Capital Management first reported a position in Standard BioTools in Q3 2020 and has held it in 10 quarters since.
ExodusPoint Capital Management's Standard BioTools position peaked at $1.37M in Q3 2020.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.